Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer  

Oleh:

Partridge, Ann H. ; Ruddy, Kathryn J. ; Gelber, Shari

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: Fertility and Sterility (keterangan: ada di ClinicalKey) vol. 94 no. 02 (Jul. 2010), page 638-644.
Topik: Ovarian reserve; breast cancer; chemotherapy; premenopausal; fertility

Ketersediaan

Perpustakaan FK Nomor Panggil: F02.K.2010.04 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

Objective To compare markers of ovarian reserve between women exposed to cytotoxic chemotherapy for early stage breast cancer and matched controls. Design Cross-sectional evaluation of markers of ovarian reserve. Setting Dana-Farber/Brigham and Women's Cancer Center, Massachusetts General Hospital, and Faulkner Hospital in Boston, MA. Patient(s) Breast cancer survivors with continued menses after chemotherapy were compared with age-matched, gravidity-matched controls. Main Outcome Measure(s) Antral follicle count (AFC), anti-Müllerian hormone (AMH), FSH, inhibin B (InB), and E2 on day 2, 3, or 4 of the menstrual cycle. A Bonferroni correction was performed to correct for multiple comparisons. Result(s) Twenty survivors and 20 controls were evaluated; 50% of survivors were currently on tamoxifen. Median AFC was 6 for survivors and 9.5 for controls. There were significant differences between the two groups in AFC, AMH, and nonsignificant differences in FSH and InB, all indicating better ovarian reserve in controls. The AFC and AMH levels were highly correlated (r = 0.72). Survivors on tamoxifen had lower AFC, AMH, InB, and higher E2 than nontamoxifen–treated survivors. Conclusion(s) Premenopausal breast cancer survivors have diminished ovarian reserve compared with controls.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali